Fig. 2

Change from baseline in LEI/SPARCC (patients with LEI > 0/SPARCC > 0 at baseline). *Indicates a comparison where the 95% CI for tofacitinib does not overlap with the 95% CI for placebo. ^aEach site was assessed bilaterally, and results were combined. Δ, change from baseline; BID, twice daily; CI, confidence interval; LEI, Leeds Enthesitis Index; M, month; N, total number of patients with LEI > 0 or SPARCC > 0 in that particular location or number of affected sites at baseline; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index